Across all domains of life, immune defenses foil invading viruses by making it impossible for the viruses to replicate. Most ...

Innovative research into the gene-editing tool targets influenza’s ability to replicate—stopping it in its tracks.

CRISPR Therapeutics (NASDAQ:CRSP) is one of the best emerging technology stocks to invest in. On December 22, CRISPR ...

Scientists have developed a novel approach of genome editing to repair muscle stem (satellite) cells, offering new hope for ...

Researchers say discoveries could expand the CRISPR toolbox and lead to more efficient, rapid diagnostic tools for detecting COVID-19, influenza, and RSV.

Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex ...

CHANGE-seq-BE was developed to enable scientists to better understand base editors, an important class of CRISPR precise genome editors.

Technologies at the Advanced Rodent Transgenics Laboratory include genome editing design and implementation and transgenic ...

TheFly published on November 26, 2025, that Chardan kept its buy recommendation on CRISPR Therapeutics AG (NASDAQ:CRSP) while ...